Trial Profile
BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Ixabepilone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms BrUOG-Pros-221
- 13 Feb 2017 Status changed from active, no longer recruiting to completed.
- 18 Jul 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
- 17 Jun 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as per ClinicalTrials.gov record.